In a six-month trial, people with Type 1 diabetes and obesity who ate only between noon and 8 p.m. saw better glucose control than calorie-cutters — with no rise in the dangerous highs and lows that make fasting fraught in this group.
UCLA researchers grew trillions of tumor-hunting T cells from a few cord-blood stem cells — enough for thousands of doses — and, in mice, controlled cancer without the dangerous complication that has long plagued donor-cell therapies.
Interim trial data showed up to 79% fewer monthly seizures after a single dose — and now Encoded Therapeutics has fresh funding to drive its Dravet syndrome gene therapy toward pivotal trials.
The expanded accelerated approval lets patients with HER2-mutant non-small cell lung cancer take sevabertinib right away, without first having to try chemotherapy.
Studies increasingly tie Helicobacter pylori infection to colorectal cancer, but whether treating the bug lowers that risk remains genuinely unsettled.
ARPA-H’s new ADVOCATE program aims to build the first FDA-authorized “agentic” AI that can autonomously help manage heart-failure care — assessing symptoms, ordering labs, even adjusting medications.
The new immuno-oncology company is betting a next-generation CTLA-4 antibody with a short half-life can crack “cold” colon tumors that resist today’s immunotherapy.
At a major lung conference, AstraZeneca reported that its IL-33 inhibitor tozorakimab significantly reduced the airway-clogging mucus plugs that worsen COPD — a first for a biologic.
An intravenous gene therapy extended survival up to threefold and eased symptoms in cats with Sandhoff disease — an early but hopeful step toward treating a disorder that usually kills children by age four.
A new American Cancer Society–WHO analysis projects annual cancer diagnoses rising from 21 million to 34 million by 2050, driven mostly by aging and population growth — with the heaviest burden falling on poorer countries.
A 132,000-person Danish study found people who began statins within a year of a type 2 diabetes diagnosis had a 15% lower 10-year dementia risk — though, being observational, it can’t prove the drugs are the cause.
BrainChild Bio is betting that delivering engineered immune cells directly into the brain — not through the bloodstream — can finally reach some of the deadliest childhood cancers.